Clinical trials of Rimostil, a plant-based estrogen made from isoflavones, indicate it helps prevent osteoporosis and heart disease in menopausal women.
The results, outlined at the recent North American Menopause Society's annual conference, show Rimostil was able to increase bone density and HDL or "good" cholesterol without any adverse side effects in women tested.
Rimostil, developed by the Connecticut-based Novogen Inc., is set for release next year and differs from regular estrogen in its mixture of different plant isoflavones. Studies show it can increase cortical bone density -- the bone involved in hip fractures -- by 4 percent over six months, well beyond what regular estrogen therapy has recorded.
Researchers say the drug also raised good cholesterol levels by 28 percent, for many women a return to pre-menopausal levels. Dr. Lila Nachtigall, of the Women's Wellness Program at New York University, says Rimostil "clearly addresses the need to safely regulate hormone levels in post-menopausal women, with the emphasis on the word 'safely.'"
No comments:
Post a Comment